$0.66 Earnings Per Share Expected for West Pharmaceutical Services Inc. (WST) This Quarter

Brokerages predict that West Pharmaceutical Services Inc. (NYSE:WST) will report earnings per share (EPS) of $0.66 for the current quarter, according to Zacks. Two analysts have issued estimates for West Pharmaceutical Services’ earnings. The lowest EPS estimate is $0.63 and the highest is $0.67. West Pharmaceutical Services posted earnings per share of $0.51 in the same quarter last year, which suggests a positive year-over-year growth rate of 29.4%. The company is scheduled to announce its next quarterly earnings report on Thursday, July 26th.

According to Zacks, analysts expect that West Pharmaceutical Services will report full-year earnings of $2.81 per share for the current fiscal year, with EPS estimates ranging from $2.80 to $2.83. For the next year, analysts expect that the company will post earnings of $3.22 per share, with EPS estimates ranging from $3.14 to $3.35. Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for West Pharmaceutical Services.

West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, April 26th. The medical instruments supplier reported $0.62 EPS for the quarter, missing the consensus estimate of $0.64 by ($0.02). West Pharmaceutical Services had a net margin of 8.20% and a return on equity of 14.40%. The business had revenue of $415.70 million for the quarter, compared to analyst estimates of $403.87 million. During the same period in the prior year, the company earned $0.60 earnings per share. The firm’s revenue for the quarter was up 7.2% on a year-over-year basis.

Several equities research analysts recently commented on WST shares. ValuEngine upgraded shares of West Pharmaceutical Services from a “sell” rating to a “hold” rating in a research report on Tuesday, June 12th. Zacks Investment Research upgraded shares of West Pharmaceutical Services from a “sell” rating to a “hold” rating in a research report on Saturday, June 2nd. Finally, Bank of America downgraded shares of West Pharmaceutical Services from a “neutral” rating to an “underperform” rating and set a $85.00 price target for the company. in a research report on Wednesday, April 25th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $106.00.

In related news, CFO William J. Federici sold 52,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 9th. The shares were sold at an average price of $87.14, for a total value of $4,531,280.00. Following the completion of the sale, the chief financial officer now owns 247,019 shares in the company, valued at approximately $21,525,235.66. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Daniel Malone sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, June 11th. The shares were sold at an average price of $97.24, for a total transaction of $486,200.00. Following the completion of the sale, the vice president now owns 34,020 shares of the company’s stock, valued at approximately $3,308,104.80. The disclosure for this sale can be found here. In the last 90 days, insiders sold 99,869 shares of company stock valued at $9,136,762. 1.90% of the stock is owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in WST. California Public Employees Retirement System lifted its position in West Pharmaceutical Services by 3.0% in the 4th quarter. California Public Employees Retirement System now owns 162,472 shares of the medical instruments supplier’s stock worth $16,031,000 after buying an additional 4,713 shares in the last quarter. Sei Investments Co. lifted its position in West Pharmaceutical Services by 35.7% in the 4th quarter. Sei Investments Co. now owns 36,328 shares of the medical instruments supplier’s stock worth $3,584,000 after buying an additional 9,566 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in West Pharmaceutical Services by 13.3% in the 4th quarter. The Manufacturers Life Insurance Company now owns 123,208 shares of the medical instruments supplier’s stock worth $12,158,000 after buying an additional 14,471 shares in the last quarter. Arizona State Retirement System lifted its position in West Pharmaceutical Services by 27.3% in the 4th quarter. Arizona State Retirement System now owns 53,447 shares of the medical instruments supplier’s stock worth $5,274,000 after buying an additional 11,477 shares in the last quarter. Finally, BlackRock Inc. lifted its position in West Pharmaceutical Services by 5.8% in the 4th quarter. BlackRock Inc. now owns 6,230,224 shares of the medical instruments supplier’s stock worth $614,734,000 after buying an additional 341,999 shares in the last quarter. Institutional investors own 94.45% of the company’s stock.

WST stock opened at $100.99 on Friday. The company has a quick ratio of 2.00, a current ratio of 2.82 and a debt-to-equity ratio of 0.15. The company has a market cap of $7.43 billion, a P/E ratio of 36.33, a price-to-earnings-growth ratio of 3.27 and a beta of 1.11. West Pharmaceutical Services has a 12 month low of $80.02 and a 12 month high of $103.36.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, August 1st. Investors of record on Wednesday, July 18th will be given a $0.14 dividend. The ex-dividend date is Tuesday, July 17th. This represents a $0.56 annualized dividend and a dividend yield of 0.55%. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 20.14%.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.

Get a free copy of the Zacks research report on West Pharmaceutical Services (WST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply